6. Lipid Metabolism

Learning Objectives

• Describe the structure and classification of major lipid classes (triglycerides, phospholipids, sterols, fatty acids)
• Trace the steps of beta-oxidation and calculate ATP yield from a fatty acid
• Explain de novo lipogenesis and how it is regulated by insulin and glucagon
• Describe ketone body synthesis and identify the clinical settings in which it becomes pathological
• Compare the major lipoprotein classes (chylomicrons, VLDL, LDL, HDL) and their roles in lipid transport
• Connect defects in lipid metabolism to clinical conditions such as diabetic ketoacidosis, atherosclerosis, and fatty acid oxidation disorders

Quick Answer

Lipid metabolism is the set of pathways cells use to store, mobilize, and oxidize fats for energy, and to build membranes and signaling molecules. The four pillars are lipolysis (releasing fatty acids from stored triglycerides), beta-oxidation (breaking fatty acids down into acetyl-CoA for ATP production), de novo lipogenesis (building fatty acids from excess glucose), and ketogenesis (converting acetyl-CoA into ketone bodies when glucose is scarce). These pathways are switched on and off by insulin (favors storage) and glucagon/epinephrine (favors mobilization). Lipid metabolism matters clinically because its failure or dysregulation underlies diabetic ketoacidosis, atherosclerosis, fatty liver disease, and inherited fatty acid oxidation disorders that cause fasting hypoglycemia in children.

Introduction to Lipids

Lipids are a chemically diverse group of molecules united by one property: they are hydrophobic or amphipathic and do not dissolve well in water. The major classes are:

• Triglycerides (fats) — the body's main energy storage form, packed into adipocytes
• Phospholipids — the structural backbone of every cell membrane
• Sterols — cholesterol and its derivatives (steroid hormones, bile acids, vitamin D)
• Sphingolipids — components of myelin and cell-signaling molecules
• Waxes — protective, highly hydrophobic esters (skin, hair)

This chapter focuses on triglycerides and their fatty acid components, since these dominate energy metabolism and are the most heavily tested pathways in medical biochemistry.

Structure of Triglycerides and Fatty Acids

A triglyceride is glycerol esterified to three fatty acid chains — C₃H₅(OOCR)₃, where R is the fatty acid's hydrocarbon tail. Because each ester bond releases a water molecule during synthesis, triglycerides are extremely energy-dense (9 kcal/g versus 4 kcal/g for carbohydrate or protein) — this is precisely why adipose tissue, not glycogen, is the body's long-term fuel reserve.

Fatty acids are classified by their carbon-carbon bonds:

1. Saturated fatty acids — no double bonds; pack tightly and are solid at room temperature (palmitic acid, stearic acid)
2. Monounsaturated fatty acids — one double bond (oleic acid)
3. Polyunsaturated fatty acids — two or more double bonds (linoleic acid, an essential fatty acid the body cannot synthesize)

The degree of unsaturation determines membrane fluidity: more double bonds introduce kinks in the chain, so membranes rich in unsaturated fatty acids stay fluid at lower temperatures — a key reason fish (cold environments) have highly unsaturated membrane lipids.

Lipid Metabolism Pathways

Four pathways dominate lipid metabolism, and the body switches between them based on fed/fasted state:

De Novo Lipogenesis

De novo lipogenesis converts excess dietary glucose into fatty acids when energy intake exceeds immediate need. It occurs mainly in the liver and, to a lesser extent, adipose tissue, and runs in the cytoplasm — the mirror-image compartment to beta-oxidation, which runs in mitochondria.

Key enzymes:

• Acetyl-CoA carboxylase (ACC) — the committed, rate-limiting step; converts acetyl-CoA to malonyl-CoA. Activated by insulin and citrate; inhibited by glucagon-driven phosphorylation and by palmitoyl-CoA (feedback inhibition).
• Fatty acid synthase (FAS) — a multi-enzyme complex that elongates the chain two carbons at a time using malonyl-CoA, ultimately producing palmitate (16 carbons).

Clinically important: malonyl-CoA, the product of ACC, also inhibits carnitine palmitoyltransferase I (CPT-I), the enzyme that commits fatty acids to oxidation. This is the master switch — when the cell is making fat, it simultaneously blocks fat breakdown, preventing a futile cycle.

Lipolysis

Lipolysis breaks stored triglycerides into glycerol and free fatty acids inside adipocytes, releasing fuel for other tissues.

Key enzymes:

• Adipose triglyceride lipase (ATGL) — removes the first fatty acid
• Hormone-sensitive lipase (HSL) — removes the second; activated by protein kinase A after epinephrine or glucagon binds their receptors and raises cAMP
• Monoacylglycerol lipase — removes the final fatty acid

Insulin does the opposite: it activates a phosphatase that dephosphorylates and inactivates HSL, shutting lipolysis down. This insulin/glucagon-epinephrine tug-of-war on HSL is a favorite USMLE testing point.

Beta-Oxidation

Beta-oxidation is the mitochondrial pathway that chops a fatty acid down into two-carbon acetyl-CoA units, feeding the TCA cycle.

The carnitine shuttle (the gatekeeper): Long-chain fatty acids cannot cross the inner mitochondrial membrane as acyl-CoA, so they are shuttled across as acylcarnitine.

• CPT-I (outer mitochondrial membrane) — converts fatty acyl-CoA to fatty acylcarnitine; this is the rate-limiting, glucagon-favored, malonyl-CoA-inhibited step
• Carnitine-acylcarnitine translocase moves it across the inner membrane
• CPT-II (matrix side) — regenerates fatty acyl-CoA for oxidation

The four repeating reactions (each cycle shortens the chain by 2 carbons and yields one FADH₂, one NADH, and one acetyl-CoA):

1. Oxidation by acyl-CoA dehydrogenase (FAD → FADH₂)
2. Hydration
3. Oxidation (NAD⁺ → NADH)
4. Thiolytic cleavage (releases acetyl-CoA)

Worked example — palmitate (16 carbons): Beta-oxidation runs 7 cycles, producing 8 acetyl-CoA, 7 FADH₂, and 7 NADH. Running the numbers through oxidative phosphorylation (roughly 1.5 ATP/FADH₂, 2.5 ATP/NADH, 10 ATP/acetyl-CoA via TCA) gives about 106 ATP, minus 2 ATP spent activating the fatty acid initially — a net of ~104-106 ATP per palmitate molecule. This is why fat is such an efficient fuel store compared to glucose (~32 ATP per glucose).

Medium- and short-chain fatty acids bypass the carnitine shuttle entirely (they diffuse directly into mitochondria), which is clinically relevant in treating fatty acid oxidation disorders — MCT (medium-chain triglyceride) oil is used as a dietary workaround.

Ketone Body Synthesis (Ketogenesis)

When beta-oxidation generates acetyl-CoA faster than the TCA cycle and oxaloacetate supply can handle (classically during fasting, low-carbohydrate diets, or uncontrolled diabetes), the liver diverts acetyl-CoA into ketone bodies: acetoacetate, beta-hydroxybutyrate, and acetone.

Key enzymes:

• HMG-CoA synthase — the rate-limiting, liver-mitochondria-specific enzyme that commits acetyl-CoA to ketogenesis
• HMG-CoA lyase — cleaves HMG-CoA to acetoacetate

Ketone bodies are water-soluble and can cross the blood-brain barrier, making them a vital alternative fuel for the brain during prolonged fasting (the brain cannot use fatty acids directly). Peripheral tissues reconvert beta-hydroxybutyrate to acetoacetate and then to acetyl-CoA using an enzyme the liver deliberately lacks (succinyl-CoA:3-ketoacid CoA transferase, or SCOT) — this is why the liver produces ketones but cannot consume its own product.

Regulation of Lipid Metabolism

The lipogenesis/lipolysis switch is hormonally controlled:

1. Insulin — activates lipogenesis (ACC) and lipoprotein lipase; inactivates HSL. Dominant in the fed state.
2. Glucagon and epinephrine — activate HSL via cAMP/PKA, promoting lipolysis and ketogenesis. Dominant in the fasted/stressed state.
3. Cortisol — promotes lipolysis and, over longer time frames, redistributes fat (Cushing syndrome's central obesity).
4. Growth hormone — promotes lipolysis, sparing glucose for the brain.
5. Thyroid hormone — increases the metabolic rate of both lipogenesis and lipolysis; hyperthyroidism accelerates lipid turnover and weight loss.

Lipoprotein Transport

Because lipids are hydrophobic, they cannot travel freely in the aqueous bloodstream — they are packaged into lipoproteins, spherical particles with a hydrophobic triglyceride/cholesteryl ester core and an amphipathic phospholipid/apolipoprotein shell.

Lipoprotein	Origin	Main Cargo	Key Apolipoprotein	Role
Chylomicrons	Intestine	Dietary triglycerides	ApoB-48, ApoC-II	Deliver dietary fat to peripheral tissues and liver
VLDL	Liver	Endogenous triglycerides	ApoB-100, ApoC-II	Export liver-made triglycerides to tissues
IDL	VLDL remnant	Triglycerides + cholesterol	ApoE	Intermediate; taken up by liver or converted to LDL
LDL	IDL remnant	Cholesterol (cholesteryl esters)	ApoB-100	Delivers cholesterol to peripheral tissues; the "bad" cholesterol carrier — excess drives atherosclerosis
HDL	Liver/intestine	Cholesterol	ApoA-I	Reverse cholesterol transport from tissues back to the liver; the "good" cholesterol carrier

Lipoprotein lipase (LPL), anchored on capillary endothelium in muscle and adipose tissue, hydrolyzes the triglycerides in chylomicrons and VLDL — its activator, ApoC-II, is why a genetic ApoC-II deficiency causes severe hypertriglyceridemia despite normal LPL protein.

Cholesterol synthesis itself is regulated at HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate. This is the enzyme statins inhibit — blocking it lowers intracellular cholesterol, which upregulates LDL receptor expression and pulls more LDL out of the blood.

Clinical Implications

Lipid metabolism disorders span a wide clinical spectrum:

1. Diabetic ketoacidosis — uncontrolled type 1 diabetes causes unchecked lipolysis and ketogenesis, producing severe metabolic acidosis and a fruity (acetone) breath odor
2. Atherosclerosis — elevated LDL and oxidized LDL deposit in arterial walls, triggering the plaque formation that underlies most myocardial infarctions and strokes
3. Non-alcoholic fatty liver disease (NAFLD) — excess triglyceride accumulation in hepatocytes, often linked to insulin resistance
4. Fatty acid oxidation disorders (e.g., MCAD deficiency) — inherited enzyme defects in beta-oxidation cause fasting hypoglycemia because the body cannot mobilize fat for energy, forcing continued glucose consumption without the ketone "backup fuel"
5. Familial hypercholesterolemia — LDL receptor mutations cause markedly elevated LDL from birth and early cardiovascular disease

Key Terms

Term	Definition	Related Concept
Triglyceride	Glycerol esterified to three fatty acids; the body's main stored fuel	Lipolysis, adipocyte
Beta-oxidation	Mitochondrial pathway that cleaves fatty acids into acetyl-CoA, 2 carbons at a time	Carnitine shuttle, TCA cycle
Carnitine shuttle	Transport system (CPT-I, translocase, CPT-II) moving long-chain fatty acids into mitochondria	CPT-I, malonyl-CoA inhibition
Malonyl-CoA	Product of acetyl-CoA carboxylase; substrate for fatty acid synthesis and inhibitor of CPT-I	Lipogenesis, beta-oxidation regulation
Ketogenesis	Liver pathway converting excess acetyl-CoA into ketone bodies during fasting	HMG-CoA synthase, diabetic ketoacidosis
Ketone bodies	Acetoacetate, beta-hydroxybutyrate, and acetone; alternative brain fuel during fasting	Ketogenesis, ketoacidosis
Lipoprotein lipase (LPL)	Endothelial enzyme that hydrolyzes triglycerides in chylomicrons and VLDL	ApoC-II, hypertriglyceridemia
LDL	Lipoprotein delivering cholesterol to tissues; elevated levels drive atherosclerosis	ApoB-100, LDL receptor
HDL	Lipoprotein carrying cholesterol from tissues back to the liver (reverse transport)	ApoA-I, cardioprotection
HMG-CoA reductase	Rate-limiting enzyme of cholesterol synthesis; target of statin drugs	Mevalonate pathway, statins
Hormone-sensitive lipase (HSL)	Enzyme releasing fatty acids from stored triglycerides; activated by glucagon/epinephrine via PKA	Lipolysis, cAMP signaling
Essential fatty acid	Fatty acid the body cannot synthesize and must obtain from diet (e.g., linoleic acid)	Polyunsaturated fatty acids

Common Mistakes

Misconception: Ketone bodies are simply a toxic waste product of fat metabolism. Why it's wrong: Ketone bodies are a normal, essential fuel source. The brain, which cannot use fatty acids directly, relies heavily on ketones during prolonged fasting or starvation. Mild ketosis (as in a ketogenic diet or overnight fasting) is physiological, not pathological. Correct understanding: Ketone bodies only become dangerous when produced in excess and unregulated, as in diabetic ketoacidosis, where the accompanying hyperglycemia and lack of insulin let ketone production spiral without the normal feedback brakes, causing severe acidosis.

---

Misconception: Fatty acid synthesis is simply beta-oxidation running in reverse. Why it's wrong: The two pathways use different enzymes, different cofactors (NADPH for synthesis versus FAD/NAD⁺ for oxidation), occur in different cellular compartments (cytoplasm versus mitochondria), and are regulated reciprocally rather than being the same reaction reversed. Correct understanding: Lipogenesis and beta-oxidation are distinct pathways that are deliberately kept separate so the cell can turn one on while turning the other off — the shared regulatory link is malonyl-CoA, which activates synthesis while simultaneously blocking CPT-I-mediated oxidation.

---

Misconception: LDL is "bad cholesterol" and HDL is "good cholesterol," as if they are different types of cholesterol. Why it's wrong: The cholesterol molecule itself is identical in every lipoprotein. What differs is the carrier particle and the direction of transport. Correct understanding: LDL delivers cholesterol from the liver to peripheral tissues (excess promotes arterial deposition), while HDL removes cholesterol from tissues and returns it to the liver for excretion (reverse cholesterol transport) — the labels describe transport direction and clinical association, not different chemical forms of cholesterol.

Comparison and Connections

Feature	Beta-Oxidation	De Novo Lipogenesis
Location	Mitochondrial matrix	Cytoplasm
Direction	Catabolic (breaks down fatty acids)	Anabolic (builds fatty acids)
Key cofactor	FAD, NAD⁺ (electron acceptors)	NADPH (electron donor)
Rate-limiting enzyme	CPT-I	Acetyl-CoA carboxylase
Hormonal trigger	Glucagon, epinephrine (fasted state)	Insulin (fed state)
Regulatory link	Inhibited by malonyl-CoA	Malonyl-CoA is its own product
Net energy effect	Produces ATP	Consumes ATP and NADPH

Practice Questions

Recall

1. Name the three ketone bodies produced during ketogenesis. Answer guidance: Acetoacetate, beta-hydroxybutyrate, and acetone. Acetoacetate and beta-hydroxybutyrate are used as fuel; acetone is volatile and exhaled, producing the classic fruity breath odor of ketoacidosis.

2. What is the rate-limiting enzyme of beta-oxidation, and where is it located? Answer guidance: Carnitine palmitoyltransferase I (CPT-I), located on the outer mitochondrial membrane. It converts fatty acyl-CoA to fatty acylcarnitine so the fatty acid can cross into the mitochondrial matrix.

Understanding

3. Explain why malonyl-CoA is described as the molecular link between fatty acid synthesis and fatty acid oxidation. Answer guidance: Malonyl-CoA is the product of acetyl-CoA carboxylase, the committed step of lipogenesis. It also directly inhibits CPT-I, the committed step of beta-oxidation. So when the cell is actively synthesizing fat (high malonyl-CoA), it automatically suppresses fat breakdown, preventing a futile cycle of simultaneous synthesis and oxidation.

4. Why can the liver produce ketone bodies but not use them as fuel itself? Answer guidance: The liver lacks succinyl-CoA:3-ketoacid CoA transferase (SCOT), the enzyme required to reactivate acetoacetate back to acetoacetyl-CoA for entry into the TCA cycle. Peripheral tissues (brain, muscle, heart) possess this enzyme, so they can use ketones as fuel while the liver exports them instead.

Application

5. A 6-year-old presents with lethargy and hypoglycemia after an overnight fast during a viral illness, with low serum ketones despite low blood glucose. What defect should be suspected, and why? Answer guidance: This presentation (hypoglycemia with inappropriately low ketones) suggests a fatty acid oxidation disorder such as MCAD (medium-chain acyl-CoA dehydrogenase) deficiency. Normally, fasting triggers lipolysis and beta-oxidation, which should raise ketone levels to spare glucose. If beta-oxidation is blocked, the body cannot generate ketones or ATP from fat, so it depletes glucose reserves faster and cannot compensate, producing hypoglycemia without the expected ketosis.

6. A patient on a statin has a follow-up lipid panel showing decreased LDL. Explain the biochemical mechanism. Answer guidance: Statins competitively inhibit HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis, lowering intracellular cholesterol. The cell responds by upregulating LDL receptor expression (via SREBP transcription factors) to import more cholesterol from the blood, which increases hepatic uptake of circulating LDL and lowers serum LDL levels.

Analysis

7. Compare what happens to acetyl-CoA in a well-fed state versus a prolonged fasting state, and explain why the same molecule takes different paths. Answer guidance: In the fed state, insulin promotes citrate export from mitochondria to cytoplasm, where citrate is cleaved back to acetyl-CoA and channeled into de novo lipogenesis for storage. In prolonged fasting, acetyl-CoA is generated by beta-oxidation faster than oxaloacetate (needed for the TCA cycle) is available — because oxaloacetate is being diverted to gluconeogenesis — so excess acetyl-CoA is shunted into ketogenesis instead. The fate of acetyl-CoA is determined by hormonal state and the availability of TCA cycle intermediates, not by the molecule itself.

8. A patient with an ApoC-II deficiency presents with severe hypertriglyceridemia despite having normal lipoprotein lipase (LPL) protein levels. Explain this apparent contradiction. Answer guidance: LPL requires ApoC-II, found on chylomicrons and VLDL, as an obligate cofactor to hydrolyze triglycerides efficiently. Without ApoC-II, LPL protein is present but functionally inactive, so chylomicrons and VLDL accumulate in the blood unmetabolized, causing severe hypertriglyceridemia. This illustrates that enzyme activity depends on cofactors, not just enzyme quantity.

FAQ

1. Why does fat yield so much more energy than carbohydrate per gram? Fatty acid carbons are almost fully reduced (mostly C-H and C-C bonds), so their oxidation releases far more electrons to the electron transport chain per gram than the more oxidized carbons of glucose. This is also why triglycerides, not glycogen, are the body's long-term energy reserve — you'd need roughly six times the stored mass of glycogen to hold the same energy as fat.

2. Is a ketogenic diet dangerous? Nutritional ketosis (achieved through carbohydrate restriction) and diabetic ketoacidosis are physiologically different states. In nutritional ketosis, insulin is still present and regulates ketone production within a safe range (typically under 3-5 mM). In diabetic ketoacidosis, absolute or near-absolute insulin deficiency removes the regulatory brake entirely, allowing ketone levels to rise unchecked (often >20 mM) alongside severe hyperglycemia and acidosis. The diet itself is not the same as the disease state.

3. Why do statins cause muscle pain in some patients? HMG-CoA reductase inhibition doesn't just block cholesterol synthesis — it also reduces production of intermediates in the mevalonate pathway needed for coenzyme Q10 synthesis, which supports mitochondrial energy production in muscle. Reduced CoQ10 availability is one proposed mechanism behind statin-associated myopathy, though the full mechanism is still debated.

4. How is beta-oxidation different for odd-chain versus even-chain fatty acids? Even-chain fatty acids break down completely into acetyl-CoA. Odd-chain fatty acids leave one leftover 3-carbon unit, propionyl-CoA, which is converted (via methylmalonyl-CoA, using vitamin B12 as a cofactor) into succinyl-CoA, entering the TCA cycle directly. This is why vitamin B12 deficiency can cause a buildup of methylmalonic acid, a useful diagnostic clue.

5. Why is HDL called "good cholesterol" if cholesterol itself isn't good or bad? HDL's job is reverse cholesterol transport — picking up excess cholesterol from peripheral tissues (including arterial walls) and returning it to the liver for excretion in bile. Higher HDL levels correlate with lower cardiovascular risk because this process actively removes cholesterol from places it could accumulate, rather than depositing it there, which is what excess LDL tends to do.

Quick Revision

• Triglycerides = glycerol + 3 fatty acids; store 9 kcal/g, roughly double the energy density of carbohydrate or protein
• Lipolysis (ATGL, then HSL) releases fatty acids and glycerol from stored fat; activated by glucagon/epinephrine via cAMP-PKA, shut off by insulin
• Beta-oxidation happens in mitochondria; the carnitine shuttle (CPT-I to translocase to CPT-II) is required for long-chain fatty acids to enter
• CPT-I is the rate-limiting enzyme of beta-oxidation and is inhibited by malonyl-CoA
• Each beta-oxidation cycle removes 2 carbons and yields 1 FADH₂, 1 NADH, and 1 acetyl-CoA; palmitate yields roughly 106 net ATP
• De novo lipogenesis (cytoplasmic) uses acetyl-CoA carboxylase (rate-limiting, makes malonyl-CoA) and fatty acid synthase; requires NADPH
• Ketogenesis converts excess hepatic acetyl-CoA into acetoacetate, beta-hydroxybutyrate, and acetone via HMG-CoA synthase/lyase
• The liver cannot use its own ketones (lacks SCOT); peripheral tissues, especially the brain during fasting, use them as fuel
• Lipoproteins transport lipids in blood: chylomicrons (dietary fat), VLDL (liver-made fat), LDL (cholesterol to tissues, atherogenic), HDL (cholesterol back to liver, protective)
• HMG-CoA reductase is the rate-limiting step of cholesterol synthesis and the target of statins
• Insulin favors storage (lipogenesis, LPL activation, HSL inhibition); glucagon/epinephrine favor mobilization (lipolysis, ketogenesis)
• Diabetic ketoacidosis results when absent insulin removes the normal brake on lipolysis and ketogenesis

Related Topics

Prerequisites: Introduction to Biochemistry (enzymes, catabolism/anabolism), Carbohydrate Metabolism (glycolysis and the TCA cycle, since acetyl-CoA and oxaloacetate link the pathways)

Related Topics: Cholesterol and Steroid Hormone Synthesis, Amino Acid Metabolism (shared entry points into the TCA cycle), Endocrine Regulation of Metabolism (insulin and glucagon signaling)

Next Topics: Protein Metabolism and the Urea Cycle, Integration of Metabolism (fed versus fasted state), Clinical Biochemistry of Metabolic Disease (dyslipidemia, diabetes, inborn errors of metabolism)

---

This page is for educational purposes. Always verify with current clinical guidelines.